Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 19, 2014

View Archived Issues

Otsuka Pharmaceutical recaps highlights of second quarter of fiscal 2014

Trevena releases data from phase IIa/b study of TRV-130 in acute postoperative pain

ObsEva initiates phase II trial of oxytocin receptor antagonist in women undergoing embryo transfer

Wilson Therapeutics begins phase II study of WTX-101 in Wilson disease

Validation of the antifibrogenic activity of a peripherally restricted CB1 antagonist

First possible biomarker for liver disease in alpha-1 antitypsin deficiency identified

RALDH 1 explored as a target for treating obesity and diabetes

Trumenba launched in the U.S.

JCAR-015 leukemia T-cell therapy granted FDA orphan drug designation

Hemispherx's Ampligen blocks critical Ebola viral disease viral protein

P-11520031, a novel T-type calcium channel blocker for neuropathic pain

German organization reports development of anti-parasitic vaccines

The Vanderbilt University patents detail novel mAChR M1 PAMs

Ajinomoto patents glycogen synthase activators

Chong Kun Dang Holdings patent divulges novel HDAC6 inhibitors

Roche discloses new CB2 receptor agonists

Preclinical pharmacology, safety and activity profiling of dual JAK3/ITK inhibitor ARN-4079

Consortium readied to advance development of MicroNeurotrophins for ALS

Actavis completes tender offer for Durata Therapeutics

Investigators develop DNA-based vaccine against Leishmaniasis infection

Inderal approved in Japan for the inhibition of onset of hypoxic spell in RVOTO

Long-acting anticholinergic drug to treat bronchial asthma approved in Japan

Arrowhead Research seeks clearance for phase I trial of ARC-AAT for AAT deficiency

Reckitt Benckiser plans to spin off pharmaceuticals business into Indivior

European Commission grants marketing authorization to Harvoni

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.